Dade and Cardiovascular Diagnostics form distribution agreement
This article was originally published in Clinica
Dade International and Cardiovascular Diagnostics have entered into an exclusive, five-year development and distribution agreement for point-of-care haemostasis testing. Under the agreement, Dade will distribute Cardiovascular's Thrombolytic Assessment System (TAS) under a joint label to hospital and non-hospital laboratories. TAS technology includes an analyser and test cards (see Clinica No 693, p 17). The companies estimate that the agreement will result in sales of more than $100 million over the next five years.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.